IRadimed Corporation announced its Q4 and full year 2024 financial results, reporting record revenue of $19.4 million for the fourth quarter, an 11% increase compared to the same period in 2023. GAAP diluted EPS was $0.40 and non-GAAP diluted EPS was $0.44 for the fourth quarter. The company also increased its quarterly cash dividend to $0.17 per share.
Reported record revenue of $19.4 million for Q4 2024, an 11% increase year-over-year.
GAAP diluted EPS was $0.40 and non-GAAP diluted EPS was $0.44 for Q4 2024.
Increased regular quarterly cash dividend to $0.17 per share.
Construction of new facility progressing well, with completion set for mid-year.
For the full year 2025, the Company expects to report revenue of $78.0 million to $82.0 million, GAAP diluted earnings per share of $1.55 to $1.65, and non-GAAP diluted earnings per share of $1.71 to $1.81. For the first quarter of 2025 financial guidance, the Company expects revenue of $19.2 million to $19.4 million, GAAP diluted earnings per share of $0.35 to $0.39, and non-GAAP diluted earnings per share of $0.39 to $0.43
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance